Saccharomyces Boulardii — Research Profile

Yes — this is its primary advantage. S. boulardii is a yeast, so antibacterial antibiotics do not kill it. You can take it at the same time as your antibiotic without spacing doses apart. However, do not take it with antifungal medications like fluconazole, as these will kill the yeast.

Continue taking S. boulardii for at least 1-2 weeks after completing your antibiotic course. For C. difficile prevention, clinical trials used 4 weeks of supplementation. S. boulardii does not permanently colonize the gut — it washes out within 3-5 days of stopping.

Yes. S. boulardii has been extensively studied in pediatric populations and is recommended by the WHO as an adjunct for acute diarrhea in children. Standard pediatric dosing is 250mg twice daily. It is not recommended for premature infants or immunocompromised children.

The evidence base is almost entirely for the CNCM I-745 strain taken orally as lyophilized powder in capsules or sachets. No delivery format has been shown superior to another in head-to-head trials; strain identity and a viable dose matter far more than capsule versus powder. Choose whichever oral form lets you take the studied strain at a labeled dose.

The strongest evidence is for preventing antibiotic-associated diarrhea: a meta-analysis of 21 RCTs found it cut incidence from 18.7% to 8.5% (RR 0.47, NNT 10). It also shortens acute infectious diarrhea in children by roughly a day and reduces hospital stay, and as an add-on to H. pylori therapy it raised eradication rates slightly while reducing side effects. Adult meta-analysis additionally supports use for traveler's diarrhea and enteral-nutrition-related diarrhea; evidence for uses beyond these gut conditions is limited.

There is no RDA; dosing is by indication and strain. Clinical trials of CNCM I-745 used daily amounts ranging from about 50 to 1000 mg, most commonly 250-500 mg once or twice daily (for example, 250 mg twice daily in H. pylori regimens). For preventing antibiotic-associated diarrhea it is taken throughout the antibiotic course.

No trial has compared times of day, so no optimal clock time is established. For antibiotic-associated diarrhea prevention the practical timing that was studied is starting it with the antibiotic course and continuing throughout it. If you also take an oral antifungal, separate the two so the drug does not kill the yeast.

In controlled trials adverse events were uncommon and similar to placebo; one pediatric gastroenteritis meta-analysis reported no adverse drug reactions in either group. Mild gas, bloating, or constipation are the usual complaints. The serious but rare risk is fungemia (yeast in the bloodstream), which in surveillance data was essentially confined to critically ill, catheterized, or immunocompromised patients and carried a high fatality rate in those groups.

It is compatible with antibiotics, which is the basis of its main use, since it is a yeast rather than a bacterium. Oral or systemic antifungal drugs, however, can inactivate the live yeast and reduce its benefit, so they should be separated. It should be avoided in patients on significant immunosuppression or with a central venous catheter, where cases of catheter-related fungemia have occurred.

The best-supported candidates are people starting a course of antibiotics (to lower antibiotic-associated diarrhea risk, RR 0.47), children or adults with acute infectious diarrhea, and patients undergoing H. pylori eradication therapy. It should be avoided by anyone who is immunocompromised, critically ill, or has a central venous catheter, because these are the groups in which rare S. boulardii fungemia has occurred.

For acute infectious diarrhea the effect appears within days: pooled pediatric trials show it shortens diarrhea duration by roughly one day (about 20 hours in children under 5). When used to prevent antibiotic-associated diarrhea it is taken alongside the antibiotic course as prevention rather than producing a symptom you feel improving, so there is no single "kick-in" moment. It does not permanently colonize the gut, so any benefit lasts only while you keep taking it.

Nearly all trials ran only days to a few weeks, so efficacy and safety of continuous use beyond that are not well characterized; it is typically taken as a short course tied to an antibiotic regimen or a diarrheal episode. Because the yeast does not colonize permanently, it clears from the gut within days of stopping. The one serious long-term concern is not accumulation but rare bloodstream infection (fungemia) in people with central venous catheters or serious immune compromise.

No toxic upper limit has been established; trials of the CNCM I-745 strain used daily doses spanning roughly 50 to 1000 mg without dose-related toxicity, and unabsorbed yeast is cleared once you stop. The meaningful risk is not overdose but route of exposure: if live yeast reaches the bloodstream, fungemia can occur, which is why the hazard is concentrated in catheterized, critically ill, or immunocompromised patients rather than in healthy users taking oral capsules.

Unlike bacterial probiotics, S. boulardii is a yeast and is not killed by antibiotics, so it can be taken during an antibiotic course and is frequently added to H. pylori eradication regimens, where it modestly raised eradication rates (RR 1.09) and cut treatment side effects (RR 0.47). The main thing to keep apart from it is an oral or systemic antifungal drug, which can kill the live yeast and blunt its effect. It is commonly used alongside bacterial probiotic strains without known conflict.

Look for the specific strain used in the clinical trials, Saccharomyces boulardii CNCM I-745 (the strain in Florastor and Enterol), with the dose stated in mg or CFU. Generic "probiotic yeast" without a strain designation is not backed by the same evidence, since benefits are strain- and viability-dependent. Lyophilized (freeze-dried) preparations are the standard shelf-stable format used in studies.